We still pay for Agile (presumably mostly paid off now) and the EVT801 phase 1 trial. Other biotechs with a number of trials similar to Kazia have yearly cash burn over $100 million.
- Forums
- ASX - By Stock
- KZA Chart
We still pay for Agile (presumably mostly paid off now) and the...
-
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)